Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.39 |
| ▸ | MMP2 | P08253 | 12/20 | 0.39 |
| ▸ | MMP12 | P39900 | 11/20 | 0.39 |
| ▸ | MMP9 | P14780 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889497 | 0.76 | SENP1 (0.47) | HSD17B10MAPTTDP1 | |
| SCHEMBL30509203 | 0.75 | KDM4E (0.60) | KDM4EGLAGAAHSD17B10MAPT | |
| SCHEMBL5323920 | 0.75 | KDM4E (0.60) | KDM4EGLAGAAHSD17B10MAPT | |
| SCHEMBL3282007 | 0.73 | XDH (0.37) | MAPTL3MBTL1 | |
| SCHEMBL5889520 | 0.72 | HRH3 (0.52) | MMP2KDM4EHSD17B10TDP1L3MBTL1 | |
| SCHEMBL5889541 | 0.72 | TSHR (0.47) | KDM4EGAAHSD17B10POLBMAPT | |
| SCHEMBL20764158 | 0.71 | HRH4 (0.49) | MMP2KDM4EGAAHSD17B10TDP1 | |
| SCHEMBL26103828 | 0.71 | MAPT (0.46) | KDM4EGAAPOLBMAPTTDP1 | |
| SCHEMBL23235066 | 0.71 | RAB9A (0.49) | MAPT | |
| SCHEMBL5889493 | 0.71 | HDAC4 (0.42) | KDM4EHSD17B10POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-6906103-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003057212-A1 | POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000650-A9 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECH INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | MMP1 2883/4885MMP2 928/4885MMP12 783/4885 |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | MMP1 2883/4885MMP2 928/4885MMP12 783/4885 |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | MMP1 2447/4885MMP2 1498/4885MMP12 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.